TrialAnnals of hematology2023

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.

Susanne Isfort et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.